OncoCyte Corp (OCX) - Total Liabilities
Based on the latest financial reports, OncoCyte Corp (OCX) has total liabilities worth $50.14 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore OCX operating cash flow to assess how effectively this company generates cash.
OncoCyte Corp - Total Liabilities Trend (2013–2024)
This chart illustrates how OncoCyte Corp's total liabilities have evolved over time, based on quarterly financial data. Check OCX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
OncoCyte Corp Competitors by Total Liabilities
The table below lists competitors of OncoCyte Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CYGNUS Metals Ltd
AU:CY5
|
Australia | AU$7.09 Million |
|
Lily Textile Co Ltd
TW:1443
|
Taiwan | NT$6.07 Billion |
|
M & A EQUITY HOLDINGS BERHAD
KLSE:7082
|
Malaysia | RM108.85 Million |
|
Talga Group Ltd
AU:TLG
|
Australia | AU$17.10 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
USA | $40.58 Million |
|
Bioxyne Ltd
AU:BXN
|
Australia | AU$14.45 Million |
|
Golden Matrix Group Inc
NASDAQ:GMGI
|
USA | $82.68 Million |
|
Stem Inc
NYSE:STEM
|
USA | $557.95 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down OncoCyte Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OCX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OncoCyte Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OncoCyte Corp (2013–2024)
The table below shows the annual total liabilities of OncoCyte Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $47.35 Million | -3.94% |
| 2023-12-31 | $49.30 Million | -25.08% |
| 2022-12-31 | $65.80 Million | -30.26% |
| 2021-12-31 | $94.35 Million | +330.10% |
| 2020-12-31 | $21.94 Million | +143.17% |
| 2019-12-31 | $9.02 Million | +48.01% |
| 2018-12-31 | $6.09 Million | +4.85% |
| 2017-12-31 | $5.81 Million | +26.78% |
| 2016-12-31 | $4.58 Million | +98.14% |
| 2015-12-31 | $2.31 Million | -68.86% |
| 2014-12-31 | $7.43 Million | +59.03% |
| 2013-12-31 | $4.67 Million | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more